Utah Let AI Prescribe Medicine
The AI prescription pilot shows why the FDA, not a commerce department, should be setting the rules.
April 8, 2026 – 6:30 am
The case for AI prescription renewals is real. So is the case against trusting a state sandbox to catch the risks. In January, a security research firm called Mindgard sat down with a chatbot. The chatbot had been built by Doctronic, a health technology startup that had just become the first company in American history to receive state approval to autonomously renew medical prescriptions using artificial intelligence.
Mindgard’s researchers fed the AI a fabricated regulatory bulletin and watched what happened. The system, convinced by a document that did not exist, told them it would triple the standard prescribed dose of OxyContin.
Doctronic and Utah’s Office of Artificial Intelligence Policy were quick to clarify that the vulnerable chatbot was Doctronic’s public-facing tool, not the hardened system running the actual prescription pilot. That distinction matters, and it is worth taking seriously.
But it does not resolve the deeper question that the exchange raises, which is not whether this particular system was compromised, but whether a 12-month state sandbox programme, run by a commerce department with a mandate to encourage AI innovation, is the right mechanism for answering that question at all.
Start with what is genuinely true about the problem Utah is trying to solve. Prescription renewal is, for enormous numbers of Americans, a bureaucratic obstacle that serves no clinical purpose. About half of all people with chronic conditions do not take their medications as prescribed, according to the CDC. The broader challenge of making healthcare accessible and preventative, rather than reactive, is one the tech industry has been grappling with for years.
A significant portion of that non-adherence traces directly to the renewal process: the two-week wait for a primary care appointment, the missed call from the surgery, the lapsed prescription that means starting over. Managed Healthcare Executive reported that Doctronic’s co-founder Matt Pavelle puts the figure at around 30% of all non-adherence.
That is a large number attached to a concrete and fixable problem. Medication non-adherence costs the American healthcare system somewhere between $100 billion and $300 billion annually, depending on which set of studies you consult, and is associated with around 125,000 preventable deaths per year. Those are not made-up numbers from a startup’s pitch deck. They come from peer-reviewed literature and from the CDC.
The access argument for AI prescription renewals is therefore not trivial. It is strongest precisely where the care system is thinnest: rural areas, low-income patients, older Americans who struggle to attend in-person appointments.
Adam Oskowitz, the vascular surgeon who co-founded Doctronic, put it plainly in January: patients are waiting weeks for an appointment to renew a prescription for a medication they have been taking for years, for a condition that